Granza Bio, a San Francisco, CA-based therapeutic delivery platform developer, raised $7M+ in Seed funding.
The round was led by Felicis and Refactor, with participation from Y Combinator, Metaplanet, Zeno Ventures, Ritual Capital, Pioneer Fund, Oxford Angel Fund, North South Ventures, Richard Aberman, JJ Fliegelman, Eric Migicovsky, Eric Eldon, Eli Brown, Eoghan Mccabe, Benjamin Bryant, Yotam Rosenbaum, Will Olsen and Joel Meyer.
The company intends to use the funds to expand operations and its development efforts.
Founded in 2024 by a team of cancer and immunology researchers at the University of Oxford, and led by CEO Dr. Ashwin Nandakumar, and CSO Dr. Ashwin Jainarayanan, Granza Bio is a biotechnology company developing a novel delivery “shell” platform to direct therapeutic cargo to specific tissues. For their lead candidate, Granza Bio is leveraging the discovery of the immune system’s suite of weapons, “attack particles”. Utilizing their advanced delivery platform, they aim to target these particles against a range of diseases such as cancer, autoimmune disorders, and infections.
FinSMEs
04/07/2024